CAR t cell therapy: how safe is it years later?
NCT ID NCT06508775
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effectiveness of this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR T cells (immune cells engineered to target cancer)
- What this could lead to
- If successful, this could confirm that CAR T cell therapy remains safe and effective for years, supporting its use as a long-term treatment for certain blood cancers and melanoma.
- What could go wrong
- This is a long-term follow-up study, not a new treatment test. It may reveal late side effects or loss of effectiveness over time. The small size (40 people) limits how much we can conclude.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHATIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité Universitätsmedizin Berlin
RECRUITINGBerlin, 13353, Germany
-
Uniklinikum Erlangen
ACTIVE_NOT_RECRUITINGErlangen, 91054, Germany
-
Universitäts-Kinderklinik Würzburg
ACTIVE_NOT_RECRUITINGWürzburg, 97080, Germany
-
Universitätsklinikum Köln
ACTIVE_NOT_RECRUITINGCologne, 50937, Germany
-
Universitätsklinikum Münster
RECRUITINGMünster, 48149, Germany
-
Universitätsklinikum Tübingen
ACTIVE_NOT_RECRUITINGTübingen, 72076, Germany
-
Universitätsmedizin Göttingen
ACTIVE_NOT_RECRUITINGGöttingen, 37075, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
- Can a smartphone VR headset distract kids from burn pain?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- New web tool aims to help families navigate tough choices on home ventilation for children
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma